Hanlim Pharmaceutical Co., Ltd.

Mi-Jin O

Geun-Hyeog Lee

Jin-Ha Park

Mi-Jung Kim

Eun-Mi Kim

Yun-Seok Cho

Dong-Yeop Shin

Byong-Sun Choi

Jong-Hyeon Ryu

Hu-Seong Kim

Kyung-Joon Kim

Jae-Shin Kim

Jin-Sun Kim

The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.

Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof

The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.

Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration

Growing community of inventors

Gyeonggi-do, South Korea

Mi-Jin O